1
|
Jhaveri K, Curigliano G, Yap YS, Cresta S, Duhoux FP, Terret C, Takahashi S, Ulaner GA, Kundamal N, Baldoni D, Liao S, Crystal A, Juric D. Abstract PD1-08: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd1-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: LSZ102 is an orally bioavailable SERD that inhibits ER gene transcription, induces receptor degradation, and blocks ER-dependent cell growth in preclinical models. This study is evaluating LSZ102 as a single agent and in combination with the CDK 4/6 inhibitor ribociclib (LEE011) or the PI3K inhibitor alpelisib (BYL719) in patients (pts) with ER+ ABC. The LSZ102 single agent data are presented below; combination data are not discussed.
Methods: In the dose-escalation phase evaluating single-agent LSZ102 (Arm A), pts (age ≥18 years; ECOG PS 0-1) with histologically confirmed ER+ ABC and progression on endocrine therapy (ET) received LSZ102. The starting dose was 200 mg once daily. The primary objective of Arm A was to characterize the safety and tolerability of LSZ102 and identify a recommended dose for expansion (RDE). Secondary objectives included preliminary antitumor activity and pharmacokinetics (PK).
Results: As of January 22, 2018, 57 pts were enrolled to Arm A (LSZ102 200 mg, n=4; 400 mg, n=6; 450 mg fasted, n=15; 450 mg with food, n=6; 600 mg, n=20; 900 mg, n=6). Median age was 60 years, 75% (n=43) of pts had an ECOG PS of 0, 56% (n=32) had received prior fulvestrant, and 58% (n=33) had received prior CDK4/6 inhibitors; median number of prior lines of therapy (all settings) was 6. At data cut-off, 48 pts had discontinued treatment, most (n=45, 94%) due to disease progression. Dose-limiting toxicities across treatment groups included diarrhea (2 pts in the 900-mg group), vomiting (1 pt in the 600-mg group), and AST and ALT elevation (1 pt in the 450-mg with food group). The most common treatment-related adverse events (AEs) in the treatment period were diarrhea (60%), nausea (56%), and vomiting (30%). In the treatment period, treatment-related grade 3 AEs (12%) were infrequent, and there were no such grade 4 events. Six pts (11%) required dose reduction due to AEs (nausea, vomiting or diarrhea); 4/6 of the dose reductions occurred at 900 mg. Preliminary PK assessment showed rapid absorption and dose-proportional increases in LSZ102 exposure; trough concentrations were above the predicted tumorostatic concentrations at doses of ≥400 mg. Based on PK results for the 450-mg fasted and fed cohorts, LSZ102 exposure does not appear to be affected by dosing with a regular meal. Evidence of ER modulation by immunohistochemistry was observed in paired baseline and on-treatment biopsies. 18F-fluoroestradiol positron emission tomography (FES-PET) analysis (n=6) demonstrated abrogation of FES-PET signal for pts in the 450-mg and 600-mg dose groups. Seventeen pts (29.8%) had a best response of stable disease, and 1 pt, who happened to be in the 600-mg group, achieved a partial response.
Conclusion: In heavily pretreated pts, LSZ102 was well tolerated, demonstrated antitumor activity, and achieved effective exposure levels based on PK and pharmacodynamics. Food intake did not appear to significantly alter the PK profile of LSZ102. Dose escalation for LSZ102 in combination with ribociclib or alpelisib is ongoing and will be reported in a future analysis. An update on the recommended single agent dose and schedule will be presented.
Citation Format: Jhaveri K, Curigliano G, Yap Y-S, Cresta S, Duhoux FP, Terret C, Takahashi S, Ulaner GA, Kundamal N, Baldoni D, Liao S, Crystal A, Juric D. Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 for estrogen receptor-positive (ER+) advanced breast cancer (ABC) with progression on endocrine therapy (ET) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD1-08.
Collapse
Affiliation(s)
- K Jhaveri
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - G Curigliano
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - Y-S Yap
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - S Cresta
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - FP Duhoux
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - C Terret
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - S Takahashi
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - GA Ulaner
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - N Kundamal
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - D Baldoni
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - S Liao
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - A Crystal
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| | - D Juric
- Memorial Sloan Kettering Cancer Center, New York, NY; Univeristy of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
2
|
Curigliano G, Cresta S, Yap YS, Juric D, Duhoux FP, Terret C, Takahashi S, Layman RM, Kundamal N, Baldoni D, Liao S, Crystal A, Jhaveri K. Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-03-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although ET remains the basis of therapy for ER+, HER2– ABC, treatment resistance frequently occurs. Novel strategies to target the receptor and/or alternative pathways to overcome therapeutic resistance are under investigation. LSZ102 is a novel, orally bioavailable, nonsteroidal SERD. Preclinically, LSZ102 inhibits ER gene transcription, induces receptor degradation, blocks ER-dependent cell growth, and has synergistic activity with the phosphoinositide 3-kinase (PI3K)-alpha inhibitor alpelisib (BYL719). The present study is evaluating the safety and tolerability of LSZ102 plus alpelisib in patients with ER+, HER2– ABC with progression on ET.
Trial Design: This phase 1/1b, open-label study is enrolling ˜18-30 patients (men and women of any menopausal status) in Arm C of the dose-escalation part of the study, which investigates the combination of LSZ102 and alpelisib; additional study arms will investigate LSZ102 as a single agent or in combination with ribociclib. Enrollment in Arm C started after identification of a safe and tolerable single-agent dose for LSZ102. Alpelisib dosing began at 200 mg/day and will not be escalated beyond the maximum tolerated dose (MTD) determined in the alpelisib single-agent arm of study CBYL719X2101 (400 mg/day). Dose escalation of alpelisib in combination with LSZ102 is guided by BLRM and integrates Cycle 1 DLT rates, lower grade and later cycle AE, PK, PD and preliminary activity to identify a recommended dose for expansion (RDE). Patients will receive treatment until disease progression, unacceptable toxicity, or withdrawal of consent. For inclusion in the study, patients must have histologically confirmed ER+, HER2– ABC and disease progression after ET for ABC or recurrence on/within 12 months of completion of adjuvant ET. In the escalation part of the study, patients are eligible regardless of PIK3CA status. Premenopausal women must receive concomitant treatment with a gonadotropin-releasing hormone agonist. Eligible patients must have adequate bone marrow and organ function, Eastern Cooperative Oncology Group performance status of 0 or 1, and have completed and recovered from acute toxicities of radiotherapy and/or prior anticancer therapy. Exclusion criteria include symptomatic central nervous system metastases, clinically significant cardiac disease or impaired cardiac function (including a QT interval corrected for heart rate using Fridericia's formula [QTcF] >460 ms in women or >450 ms in men), uncontrolled diabetes mellitus type II (or type I), and prior treatment with a PI3K inhibitor. The primary objectives are characterization of safety and tolerability for the combination and identification of a recommended dose. Secondary objectives include characterization of pharmacokinetic properties and pharmacodynamic effects. Recruitment for Arm C is ongoing. NCT02734615
Citation Format: Curigliano G, Cresta S, Yap Y-S, Juric D, Duhoux FP, Terret C, Takahashi S, Layman RM, Kundamal N, Baldoni D, Liao S, Crystal A, Jhaveri K. Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-03-01.
Collapse
Affiliation(s)
- G Curigliano
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - S Cresta
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - Y-S Yap
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - D Juric
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - FP Duhoux
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - C Terret
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - S Takahashi
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - RM Layman
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - N Kundamal
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - D Baldoni
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - S Liao
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - A Crystal
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| | - K Jhaveri
- University of Milan, Istituto Europeo di Oncologia – IRCCS, Milan, Italy; Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy; National Cancer Centre Singapore, Singapore, Singapore; Massachusetts General Hospital, Boston, MA; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Centre Léon Bérard, Lyon, France; The Cancer Institute Hospital of JFCR, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Institutes for Biomedical Research, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for Biomedical Research, Cambridge, MA; Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|